RxDoctor Payments Data

Sunitha Menon, APRN

Nurse Practitioner · Jacksonville, FLNPI 1487013645

Payments from drug & device makers

$3,652in general payments, 2019–2025

Across 107 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$389
  • AstraZeneca$362
  • E.r. Squibb & Sons, L.L.C.$358
  • Boston Scientific$322
  • Abbott$259
  • Cvrx, Inc.$253
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,652 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$12,214
Medicare patients
155
Services billed
170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan65$66,739
JardianceEmpagliflozin51$55,879
EliquisApixaban56$52,395
Repatha SureclickEvolocumab25$29,695
FarxigaDapagliflozin Propanediol17$9,372
Metoprolol Succinate163$1,925
Atorvastatin Calcium122$1,458
Rosuvastatin Calcium117$1,098
Ezetimibe75$1,013
Carvedilol91$733
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$620
ClopidogrelClopidogrel Bisulfate32$529
Bumetanide20$525
Nifedipine ErNifedipine20$504
Losartan Potassium40$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$208$66,73965 claims
Boehringer IngelheimJardiance$217$55,87951 claims
PfizerEliquis$121$52,39556 claims
AstraZenecaFarxiga$362$9,37217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →